最终阶段的ADPKD与低频PKD1马赛克变体加快化疗放射治疗
Hiroaki Hanafusa1, Hiroshi Yamaguchi2, Naoya Morisada3
1Department of Pediatrics, Kobe University Graduate School of Medicine, Hyogo, Japan.
Human genome variation
|March 29, 2024
概括
马赛克PKD1变种通常会导致轻度自体主导多囊性病 (ADPKD). 然而,这个病例显示严重的ADPKD和末期病,这表明环境因素可能会加剧遗传倾向.
科学领域:
- 遗传学 是一个遗传学.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 在瘤学瘤学.
背景情况:
- 自体主导多囊性病 (ADPKD) 是一种常见的遗传性疾病.
- PKD1基因的突变是ADPKD的主要原因.
- 马赛克PKD1变种通常与较轻的疾病表型有关.
研究的目的:
- 介绍一个患有罕见的ADPKD病例的病例研究.
- 探索环境因素对ADPKD严重程度的潜在影响.
- 在重大医疗干预的背景下调查PKD1马赛克变异的影响.
主要方法:
- 一个32岁的男性患者的病例报告.
- 审查患者的病史,包括骨髓移植和化学放射治疗.
- 基因分析确定了一个低频的马赛克拼接PKD1变体.
- 对囊发育和疾病进展的临床评估.
主要成果:
- 患者在30多岁时发展出严重的囊和末期病.
- 确定了一种低频的马赛克拼接PKD1变体.
- 该患者有慢性活跃的爱斯坦-巴尔病毒病史,并在9岁时接受了化疗放射治疗.
结论:
- 这一案例表明,化学辐射疗法等环境因素可能会在具有马赛克PKD1变异的个体中加剧ADPKD的严重程度.
- 对ADPKD的遗传倾向可能受到外部因素的影响,导致比通常预期的更严重的表型.
- 需要进一步的研究来了解ADPKD进展中遗传变异和环境暴露之间的相互作用.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
162
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
162
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


